Business Wire

HISTALIM Will Develop Its Own Precision Medicine Tool Named HISTOPROFILE Through a Collaborative R&D Program of 29 Million Euros, Endorsed by BPIfrance

Jaa

Describe with high fidelity the tumor immune profile will be soon a major stake for an appropriate care of the patients affected by cancer. This is the promise offered by the precision medicine tool HISTOPROFILE developed by HISTALIM. To accelerate its development, HISTALIM will rely on a collaborative research & development project of 29 Million Euros, in partnership with OSE Immunotherapeutics and CESTI. This project will be funded by the Programme d’investissement d’avenir coordinated by BPIfrance.

Recent progress in immuno oncology, emergence of clinical trials combining multiple therapies, as well as multiplication of companion diagnostic tests based on immunohistochemistry converge toward the same direction: the need for the next generation histopathology to define the tumor immune profile with one single slide.

Thanks to multiplex immunohistochemistry, multispectral microscopy and image analysis, HISTALIM develop HISTOPROFILE: a complete tool of precision medicine for clinical trials in immuno oncology and which could become a new generation tool for diagnostic in histopathology.

Through this research and development project, the HISTOPROFILE tool will be used to monitor patients enrolled in several clinical phases sponsored by OSE Immunotherapeutics. The company will develop thanks to this program an innovative immune checkpoint inhibitor targeting SIRP-alpha. OSE Immunotherapeutics is a biotechnology company dedicated to the development of innovative immunotherapies to restore immune disorders in the fields of immuno-oncology, autoimmune diseases and transplantation. The company has a portfolio of advanced immunotherapy products in clinical phases 2 and 3, of promising products in preclinical phase and of potential drug candidates in R&D

The project also includes the European Center for Transplantation and Immunotherapy Sciences (CESTI), a University Hospital Institute (IHU Nantes) recognized for its reputed expertise in immunotherapy and its pertinent platform of experimental and translational research for clinical trials and innovative therapeutics development.

HISTOPROFILE will complete the service offer developed by HISTALIM for the tissue sample analysis from clinical trials lead by its customers. The success in the immuno-oncology segment mainly boost the growth of the company. In 2017 HISTALIM’s revenues are expected to progress by 20%.

https://www.linkedin.com/company/histalim

https://twitter.com/HISTALIM

Contact information

HISTALIM
Press contact :
Jean-Philippe COTON, +33619646737
contact@histalim.com
or
Tel: +33(0)4.67.712.765
contact@histalim.com
www.histalim.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

New Data for Darzalex®▼(daratumumab) Presented at ASH 2017 Show Feasibility of Subcutaneous Use and Potential of Darzalex as a Treatment for Smouldering Multiple Myeloma12.12.2017 11:00Tiedote

Janssen-Cilag International NV (“Janssen”) today announced new data from the Phase 1b PAVO clinical study, which demonstrated that the subcutaneous delivery of Darzalex® (daratumumab) co-formulated with recombinant human hyaluronidase enzyme (daratumumab-SC), was generally well-tolerated, with a 12 percent rate of infusion-related reactions (IRRs), in patients with relapsed or refractory multiple myeloma.1 These data were featured as an oral presentation at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta. Daratumumab is currently approved for intravenous (IV) administration, and results from the PAVO trial serve as the basis for an actively enrolling Phase 3 study comparing subcutaneous administration of daratumumab over 3-5 minutes with the approved IV administration in relapsed and refractory multiple myeloma patients.2 Daratumumab is currently indica

The Country Network (TCN) Debuts in Ultra HD with SES12.12.2017 10:55Tiedote

The Country Network (TCN), an emerging over-the-air television network devoted to showcasing rising and established country music stars, has joined SES’s successful Ultra HD platform to launch its 4K channel and boost its audience reach. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006280/en/ The Country Network (TCN) Debuts in Ultra HD with SES (Photo: Business Wire) SES today announced The Country Network (TCN) has debuted its first shows in Ultra HD this week and become the eleventh 4K channel on SES’s all-in-one Ultra HD solution. The unique Ultra HD platform packages satellite distribution, reception gear, and the world’s largest 4K channel line-up for cable and IPTV operators of all sizes across North America. First launched in 2009, The Country Network is currently enj

World’s First Ultra HD HDR Travel Channel Travelxp 4K Makes German Debut on HD+ via SES12.12.2017 10:55Tiedote

Travelxp 4K, one of the world’s leading travel and lifestyle television channels, will start delivering its programmes in Ultra HD (UHD) and High Dynamic Range (HDR) to HD+ viewers across Germany as of 13 December 2017. The channel will be broadcast via Astra 19.2 degrees East and will rely on MX1 for playout and uplink services. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006262/en/ World’s First Ultra HD HDR Travel Channel Travelxp 4K Makes German Debut on HD+ via SES Travelxp 4K is also one of the first networks in the world to broadcast in High Dynamic Range, a feature that provides better contrast and greatly improves the viewer experience. Thanks to that technology, HD+ customers can enjoy holiday destinations from around the world from the comfort of their own homes without any additio

Dialog Semiconductor Power Conversion Chipset Used in HUAWEI's Latest Flagship Mate 10 Series12.12.2017 10:13Tiedote

Dialog Semiconductor plc (XETRA: DLG), a provider of highly integrated power management, AC/DC power conversion, and low power connectivity technology, today announced that Dialog's RapidCharge(TM) chipset enabling the SuperCharge protocol was selected for the new HUAWEI Mate 10, HUAWEI Mate 10 Pro and Porsche Design HUAWEI Mate 10 smartphone adapters. As fast charging smartphone adoption accelerates, this represents another significant milestone in the company's AC/DC power conversion leadership as Dialog continues to maintain a market share above 60%. HUAWEI recently launched their impressive Mate 10 series with breakthrough AI devices that combine innovative hardware and software. The Kirin 970 chipset and EMUI 8.0 is the world's first AI processor for smartphones with a dedicated Neural Network Processing Unit (NPU). All HUAWEI Mate 10 series sport the New Leica Dual

Russian Teen Star Polina Butorina Releases Her Debut Album in Dubai12.12.2017 10:00Tiedote

UAE-based Russian teen actor and singer-songwriter Polina Butorina released her debut album, titled ‘Ocean of Emotions’, here. The anthology of 10 original English songs are written and sung by the 15-year-old student of Raffles International School Dubai. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006370/en/ Polina Butorina at the launch of debut album "Ocean of Emotions" - (Photo: AETOSWire) The album was launched simultaneously with the premiere of the recent Hollywood motion picture ‘Maximum Impact’, in which Polina played a main role. The album’s three tracks – ‘Higher Than the Sky’, ‘I Want to Be Free’ and ‘Like Thunder’ were part of the movie’s soundtrack. Launching the album, Polina said, “The album explores the idea of love in its different appearances. The main concept r

IDEMIA Has Been Selected by WiZink to Launch Samsung Pay in Spain12.12.2017 09:00Tiedote

IDEMIA, the global leader in trusted identities for an increasingly digital world, announced WiZink, a bank that specializes in credit cards and simple savings solutions that respond to its customers’ day-to-day needs, has selected IDEMIA to roll out the Samsung Pay mobile payment service. IDEMIA has been producing WiZink cards since the bank launched its new brand in June 2016. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171211006319/en/ (Photo: Business Wire) Backed by IDEMIA, WiZink cards can be digitalized and used with Samsung Pay for all users, while also benefiting from all innovative Samsung features and options that Samsung Pay users can access. With the novel and convenient payment method, users can add all loyalty memberships and vouchers to the same wallet under the s

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme